U.S. Organ-on-a-Chip Market Size, Share, Trends, Industry Analysis Report By Product & Services (Products, Services), By Application, By End Use

Description

List of Tables

The U.S. organ-on-a-chip market size is expected to reach USD 1,283.54 Million by 2034, according to a new study by Polaris Market Research. The report "U.S.Organ-on-a-Chip Market Size, Share, Trends, Industry Analysis Report By Product & Services (Products, Services), By Application, By End Use - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

An organ-on-a-chip is a miniature microfluidic device that uses living human cells to mimic the physiological functions and mechanical motions of an entire organ or an organ system. These chips are designed to replicate the complex environment of human organs, including their tissue structure, fluid flow, and biochemical signals. By providing a more realistic and dynamic environment than traditional cell cultures and 3D cell cultures, this technology serves as a powerful platform for a variety of applications, from disease modeling to drug screening, and represents a significant advancement in biomedical research.

The U.S. organ-on-a-chip market is a growing and evolving industry, driven by key factors such as the increasing demand for more effective and accurate methods in drug discovery. The technology offers a viable alternative to animal testing, which is often criticized for its ethical issues and poor predictive power for human responses. With a strong presence of pharmaceutical and biotechnology companies and significant R&D investments, the U.S. remains a key leader in the industry. The market is also seeing a rise in specialized services, and a trend toward the development of multi-organ chips that can model systemic interactions, further enhancing the technology's potential.

U.S. Organ-on-a-Chip Market Report Highlights:

By product & services, the services segment held the largest share in 2024, driven by the need for specialized expertise and cost-effective solutions. This is because many companies choose to outsource complex research rather than investing in expensive equipment and training.

Based on application, the drug discovery segment held the largest share in 2024. This is primarily due to the high costs and failure rates of traditional drug development, which the technology helps reduce by providing more accurate preclinical testing.

By end use, the pharmaceutical and biotechnology companies segment held the largest share in 2024. These companies are major drivers of the market due to their substantial R&D investments and their strategic need for innovative platforms to streamline drug development processes.

A few key players in the U.S. organ-on-a-chip market include Emulate, Inc.; TissUse GmbH; MIMETAS B.V.; CN Bio Innovations Ltd.; InSphero AG; AxoSim, Inc.; Hesperos, Inc.; Nortis, Inc. (Valo Health, Inc.); AlveoliX AG; Altis Biosystems, Inc.; and Cherry Biotech.

Polaris Market Research has segmented the U.S. organ-on-a-chip market report on the basis of product & services, application, and end use:

By Product & Services Outlook (Revenue - USD Million, 2020-2034)

Products

Services

By Application Outlook (Revenue - USD Million, 2020-2034)

Drug Discovery

Toxicology Research

Others

By End Use Outlook (Revenue - USD Million, 2020-2034)

Academic & Research Institutes

Pharmaceutical & Biotechnology Companies

Others

Product Code: PM6258

1. Introduction

1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
1.2. Stakeholders

2. Executive Summary

2.1. Market Highlights

3. Research Methodology

3.1. Overview
- 3.1.1. Data Mining
3.2. Data Source
- 3.2.1. Primary Source
- 3.2.2. Secondary Source

4. U.S. Organ-on-a-Chip Market Insights

4.1. U.S. Organ-on-a-Chip Market - Market Snapshot
4.2. U.S. Organ-on-a-Chip Market Dynamics
- 4.2.1. Drivers and Opportunities
  - 4.2.1.1. Growing Need for Alternatives to Animal Testing
  - 4.2.1.2. Increasing Focus on Personalized Medicine
- 4.2.2. Restraints and Challenges
  - 4.2.2.1. Regulatory uncertainty and lack of standardization
4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
4.4. PESTEL Analysis
4.5. U.S. Organ-on-a-Chip Market Application Trends
4.6. Value Chain Analysis
4.7. COVID-19 Impact Analysis

5. U.S. Organ-on-a-Chip Market, by Product and Services

5.1. Key Findings
5.2. Introduction
- 5.2.1. U.S. Organ-on-a-Chip Market, by Product and Services, 2020-2034 (USD Million)
5.3. Products
- 5.3.1. U.S. Organ-on-a-Chip Market, by Elements, by Region, 2020-2034 (USD Million)
- 5.3.2. Instrument
- 5.3.3. Devices
  - 5.3.3.1. Liver-on-a-Chip
  - 5.3.3.2. Lung-on-a-Chip
  - 5.3.3.3. Intestine-on-a-Chip
  - 5.3.3.4. Kidney-on-a-Chip
  - 5.3.3.5. Heart-on-a-Chip
  - 5.3.3.6. Others
5.4. Services
- 5.4.1. U.S. Organ-on-a-Chip Market, by Chemicals, by Region, 2020-2034 (USD Million)

6. U.S. Organ-on-a-Chip Market, by Application

6.1. Key Findings
6.2. Introduction
- 6.2.1. U.S. Organ-on-a-Chip Market, by Application, 2020-2034 (USD Million)
6.3. Drug Discovery
- 6.3.1. U.S. Organ-on-a-Chip Market, by Drug Discovery, by Region, 2020-2034 (USD Million)
6.4. Toxicology Research
- 6.4.1. U.S. Organ-on-a-Chip Market, by Toxicology Research, by Region, 2020-2034 (USD Million)
6.5. Others
- 6.5.1. U.S. Organ-on-a-Chip Market, by Others, by Region, 2020-2034 (USD Million)

7. U.S. Organ-on-a-Chip Market, by End Use

7.1. Key Findings
7.2. Introduction
- 7.2.1. U.S. Organ-on-a-Chip Market, by End Use, 2020-2034 (USD Million)
7.3. Academic & Research Institutes
- 7.3.1. U.S. Organ-on-a-Chip Market, by Academic & Research Institutes, by Region, 2020-2034 (USD Million)
7.4. Pharmaceutical & Biotechnology Companies
- 7.4.1. U.S. Organ-on-a-Chip Market, by Pharmaceutical & Biotechnology Companies, by Region, 2020-2034 (USD Million)
7.5. Others
- 7.5.1. U.S. Organ-on-a-Chip Market, by Others, by Region, 2020-2034 (USD Million)

8. Competitive Landscape

8.1. Expansion and Acquisition Analysis
- 8.1.1. Expansion
- 8.1.2. Acquisitions
8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

9.1. Altius Biosystems, Inc.
- 9.1.1. Company Overview
- 9.1.2. Financial Performance
- 9.1.3. Product Benchmarking
- 9.1.4. Recent Development
9.2. AlveoliX AG
- 9.2.1. Company Overview
- 9.2.2. Financial Performance
- 9.2.3. Product Benchmarking
- 9.2.4. Recent Development
9.3. AxoSim, Inc.
- 9.3.1. Company Overview
- 9.3.2. Financial Performance
- 9.3.3. Product Benchmarking
- 9.3.4. Recent Development
9.4. Cherry Biotech
- 9.4.1. Company Overview
- 9.4.2. Financial Performance
- 9.4.3. Product Benchmarking
- 9.4.4. Recent Development
9.5. CN Bio Innovations Ltd.
- 9.5.1. Company Overview
- 9.5.2. Financial Performance
- 9.5.3. Product Benchmarking
- 9.5.4. Recent Development
9.6. Emulate, Inc.
- 9.6.1. Company Overview
- 9.6.2. Financial Performance
- 9.6.3. Product Benchmarking
- 9.6.4. Recent Development
9.7. Hesperos, Inc.
- 9.7.1. Company Overview
- 9.7.2. Financial Performance
- 9.7.3. Product Benchmarking
- 9.7.4. Recent Development
9.8. InSphero AG
- 9.8.1. Company Overview
- 9.8.2. Financial Performance
- 9.8.3. Product Benchmarking
- 9.8.4. Recent Development
9.9. MIMETAS B.V.
- 9.9.1. Company Overview
- 9.9.2. Financial Performance
- 9.9.3. Product Benchmarking
- 9.9.4. Recent Development
9.10. TissUse GmbH
- 9.10.1. Company Overview
- 9.10.2. Financial Performance
- 9.10.3. Product Benchmarking
- 9.10.4. Recent Development
9.11. Valo Health, Inc.
- 9.11.1. Company Overview
- 9.11.2. Financial Performance
- 9.11.3. Product Benchmarking
- 9.11.4. Recent Development